Clinical Trial Update: BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment [Phase 3]

View source ↗

Summary

Phase 3 trial update on risankizumab (BI 655066/ABBV-066) in moderate to severe plaque psoriasis with randomized withdrawal and re-treatment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Risankizumab (risankizumab)

Snippet

Sponsor: AbbVie | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2019-05-28